On this #WorldSightDay (Oct. 10, 2024) ONL Therapeutics reaffirms its commitment to helping patients see the future. Our mission to develop innovative therapeutics to protect and improve the vision of patients across a range of retinal diseases and conditions drives us every day. But today, we pause to recognize the global impact of vision impairment and blindness. Learn more: https://lnkd.in/eNGA4Dz3 #WorldSightDay2024 #RetinaInnovation #Neuroprotection #ONL1204
关于我们
ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to helping patients see the future. Our mission is to develop innovative therapeutics to protect and improve the vision of patients with a range of retinal disease and conditions. By advancing a breakthrough technology designed to prevent the death of key retinal cells caused by the activation of the natural Fas pathway, ONL is pioneering an entirely new approach to preserve sight. It is the first and only company focused on preventing Fas-mediated death of key retinal cells, which is a root cause of vision loss, a leading cause of blindness and an unaddressed medical need. ONL’s lead therapeutic candidate, ONL1204, is a first-in-class small peptide Fas inhibitor designed to protect retinal cells from both death and inflammatory signaling pathways. ONL1204 Ophthalmic Solution is being developed for the treatment of retinal detachment, an acute condition for which the company has been granted orphan drug designation by the FDA. In addition, the company is currently developing ONL1204 in geographic atrophy associated with age-related macular degeneration, glaucoma, and other acute and chronic indications.
- 网站
-
https://www.onltherapeutics.com
ONL Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Ann Arbor，Michigan
- 类型
- 私人持股
- 创立
- 2011
- 领域
- Ophthalmic Drug Development、Glaucoma、Geographic Atrophy和Retinal Detachment
地点
-
主要
获取路线
524 S Main St
Suite 110
US，Michigan，Ann Arbor，48104
ONL Therapeutics员工
动态
-
Heading to the American Academy of Ophthalmology EXPO in Chicago next week? Don't miss us at booth 2439! Our team is excited to engage with fellow retina specialists about our upcoming Dry AMD/GA Phase 2 study plans, featuring a potential new treatment approach using Fas inhibition. We’re lighting the way to new AMD discoveries! #AAO2024 #RetinaInnovation #Neuroprotection #ONL1204 #DryAMD #GeographicAtrophy
-
-
We're excited to be a presenting company at Eyecelerator @ #AAO2024 in Chicago on October 17. Our co-founder and chief scientific officer David Zacks will discuss ONL1204 as a novel approach for the treatment of geographic atrophy. Join us at the RETINA SHOWCASE to learn more: https://lnkd.in/eZAenmsz #Eyecelerator #RetinaInnovation #Neuroprotection #ONL1204
-
-
October is World Blindness Awareness Month, a time to focus on the challenges faced by millions living with visual impairments and the ongoing efforts to prevent and treat blindness. According to the World Health Organization (WHO), “everyone, if they live long enough, will experience at least one eye disease or disorder in their lifetime.” At ONL Therapeutics, we are committed to helping patients see the future. Our work developing innovative therapeutics to protect retinal cells is more than just a mission—it's a passion. This month, we invite you to join us in spreading awareness about eye health. From scheduling an eye exam to supporting vision research, every action counts. #BlindnessAwarenessMonth #VisionHealth #RetinaInnovation #Neuroprotection #ONL1204
-
-
Always remember Patient #1.?Great to catch up with Professor Matthew Simunovic at the EURETINA meeting in Barcelona. Matt treated patient #1 with ONL1204 five years ago this month at the Sydney Eye Hospital. As we prepare for our 5th human trial, we owe our start to Matt and Patient #1 who said YES.?Thank you.?ONL Therapeutics
-
-
Team ONL is checking in from Barcelona at the European Society of Retina Specialists (EURETINA) Congress. Stop by booth B7 for a conversation with David Esposito, David Zacks and Lori H. to learn more about our pioneering approach to preserving vision. We're lighting the way to new AMD discoveries! #EURETINA24 #RetinaInnovation #Neuroprotection #ONL1204
-
-
Team ONL is excited to be part of the European Society of Retina Specialists (EURETINA) conference series this year in Barcelona. Our Chief Scientific Officer David Zacks launched the week at the EURETINA Innovation Spotlight, presenting "Targeting Fas Pathway: ONL Therapeutics' Approach to Dry AMD" in Session 1 on Non-neovascular AMD and IRDs. We are lighting the way to new AMD discoveries! ? #EURETINA24 #RetinaInnovation #Neuroprotection #ONL1204 #InnovationSpotlight
-
-
Big shout out to Durga S. Borkar, MD, MMCi for sharing our Phase 2 study data for Fas inhibition with intravitreal ONL1204 for the treatment of macula-off rhegmatogenous retinal detachment at The Retina Society's Scientific Meeting. Together, we will help patients see the future! #RetinaSociety2024 #RetinaInnovation #Neuroprotection #ONL1204
-
-
Thank you Lejla Vajzovic, MD, FASRS for your The Retina Society presentation on Fas inhibition with ONL1204 for the treatment of geographic atrophy. We're grateful for your dedication and commitment to helping patients see the future! #RetinaSociety2024 #RetinaInnovation #Neuroprotection #ONL1204
-
-
Using BIG for GOOD. Making strategic investments for Johnson & Johnson Innovation - JJDC
Thrilled to have Michal Silverberg and Adam Cotton from Novartis Venture Fund join #JJDC in the ONL Therapeutics syndicate! Congrats founder David Zacks and CEO David Esposito on the oversubscribed Series D ??
-